Physician profile
Carmelo Dominguez
NPI 1366401499
$1,170.31
in general payments reported to CMS, 2019-2025
18 companies · $489 in 2025
The $489 reported for 2025 was more than what 83% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $36.58 · 2024: $644 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $197.08 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $140.34 | 2024-2025 | |
| Abbvie INC. | $116.69 | 2024-2025 | |
| Amgen INC. | $109.84 | 2024-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $106.01 | 2024-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $68.53 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $62.98 | 2024 | |
| Exact Sciences Corporation | $55.01 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $43.40 | 2023-2024 | Rexulti |
| Averitas Pharma INC. | $40.47 | 2024 | Qutenza |
| Glaxosmithkline, LLC. | $39.82 | 2024-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.66 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $34.40 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.24 | 2024 | Trulance, Xifaxan |
| Eisai INC. | $23.65 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.12 | 2024 | Voquezna |
| Corcept Therapeutics | $21.75 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $15.32 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmelo Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.